PCV13 [pneumococcal 13-valent conjugate vaccine], or cohort 3: PPSV23 followed by or preceded by PCV13, PPSV23 preceded by PCV15 [pneumococcal 15-valent conjugate vaccine], or PCV15 alone).

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV ... PFE also markets Prevnar 13, which contains 13 serotypes ...

Protein conjugate bacterial vaccines for invasive pneumococcal diseases have revolutionized the epidemiology of invasive bacterial disease in young children in most of the developed world ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive ... PFE also markets Prevnar 13, which contains 13 serotypes and ...

Just a month after getting approval for its new pneumococcal vaccine ... Prevnar franchise. The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the ...

In a volatile market, growth stocks may seem like the least attractive options. That is because growth stocks are shares of companies that are still in their early stages of devel ...